Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms

Ann Oncol. 2013 Nov;24(11):2927-8. doi: 10.1093/annonc/mdt394. Epub 2013 Oct 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bilirubin / isolation & purification
  • Bilirubin / metabolism
  • Biomarkers, Pharmacological
  • Genetic Association Studies
  • Genotype
  • Gilbert Disease / chemically induced
  • Gilbert Disease / genetics
  • Gilbert Disease / pathology
  • Glucuronosyltransferase / genetics*
  • Humans
  • Hyperbilirubinemia / drug therapy
  • Hyperbilirubinemia / genetics*
  • Hyperbilirubinemia / pathology
  • Indazoles
  • Indoles / administration & dosage*
  • Indoles / adverse effects
  • Liver / drug effects
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects
  • Pyrroles / administration & dosage*
  • Pyrroles / adverse effects
  • Randomized Controlled Trials as Topic
  • Sulfonamides / administration & dosage*
  • Sulfonamides / adverse effects
  • Sunitinib

Substances

  • Biomarkers, Pharmacological
  • Indazoles
  • Indoles
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • pazopanib
  • UGT1A1 enzyme
  • Glucuronosyltransferase
  • Bilirubin
  • Sunitinib